EGFR and glioblastoma: Fusions involving the tyrosine kinase domain of EGFR have been identified in 3.7% of glioblastoma patients22, while fusions involving NTRK1, which encodes the TrkA tyrosine kinase receptor, are collectively found in 1–2.5% of glioblastomas23, 24.